The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
A preprint of ongoing work to assess effectiveness of Oxford\u2019s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 \u2018Kent\u2019 coronavirus strain currently circulating in the UK to previously circulating variants.
The launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children\u2019s pain from early years to early adulthood.
University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.
Five projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.
University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won\u2019t be ready for some weeks still.
A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting.
Dr Sarah Atkinson\u2019s research team investigates whether an iron export mutation in African populations can protect from anaemia, malaria and bacterial infections.
Collaborative research between teams from the Department of Paediatrics and the Institut de Myologie shows how antisense oligonucleotides can penetrate muscles to treat myotonic dystrophy type 1, a rare muscle disease.
The University of Oxford and Harrington Discovery Institute at University Hospitals have announced a new affiliation to advance therapies for rare diseases. The joint program combines capabilities to improve treatment options globally for patients with rare diseases.
In a Medium interview, Professor Matthew Wood, a professor of Neuroscience in the Department of Paediatrics, talks about his work and the advances that a new Rare Diseases Centre could herald for the future of rare disease and genetics.
Work published in Current Biology shows that lightly brushing in an infant can reduce pain-related brain activity evoked by a clinically necessary medical procedure.
The Lancet has published the results of the Procedural Pain in Premature Infants (Poppi) study, ran by the Paediatric Neuroimaging Group and co-ordinated by the National Perinatal Epidemiology Unit (Clinical Trials Unit).
Dr Caroline Hartley, a Senior Postdoctoral Research Fellow in the Paediatric Neuroimaging Group, has been awarded the highly competitive Sir Henry Dale Fellowship.
The Paediatric Neuroimaging research team from the Department of Paediatrics at the University of Oxford will receive a \u00a3145,987 grant from Bliss, over three years, to fund a project which seeks to improve the measurement and treatment of pain in premature babies.
There are between 11 and 27 million estimated cases of enteric fever worldwide every year, and 75,000\u2013220,000 deaths. Could vaccination stop the spread of these diesases in the environment?
![\"Jane](\"https://www.paediatrics.ox.ac.uk/news/test/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n